List of works - David R Cooper

13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model

scientific article published on January 2011

1337. Development, Maintenance, and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to Support a 20 Valent Pneumococcal Conjugate Vaccine

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate

A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.

scientific article published on 21 February 2015

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses

scientific article published on 30 September 2020

Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus

scientific article published on 18 December 2012

Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine

preprint

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors

scientific article published on 24 August 2012

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)

scientific article published on 24 December 2019

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

preprint

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

scientific article published on 12 August 2020

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

scientific article published on 20 August 2020

SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies

scientific article

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine ⬇️

scientific article published on 10 December 2020

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

scientific article published on 14 October 2020

Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study

scientific article published on 09 August 2016

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults

scientific article published on 17 August 2018

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial

scientific article published on 17 November 2016

Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention

scientific article published on 27 April 2016

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.